BRIEF published on 07/24/2024 at 12:35, 1 year 8 months ago Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Merger Financing Nasdaq Biopharmaceutical QTORIN™
PRESS RELEASE published on 07/24/2024 at 12:30, 1 year 8 months ago Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Palvella Therapeutics, Inc. and Pieris Pharmaceuticals, Inc. announce a merger to focus on rare genetic skin diseases with QTORIN™ rapamycin. Joint webcast on July 24 at 8:30am ET Merger Clinical-stage Genetic Skin Diseases QTORIN™ Rapamycin FDA-approved Therapies
BRIEF published on 04/19/2024 at 18:15, 1 year 11 months ago Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split Reverse Stock Split Nasdaq Compliance Financial Regulation Pieris Pharmaceuticals Stock Adjustment
PRESS RELEASE published on 04/19/2024 at 18:10, 1 year 11 months ago Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split Pieris Pharmaceuticals, Inc. announces a 1-for-80 reverse stock split effective on April 22, 2024, to comply with Nasdaq listing requirements. No fractional shares will be issued Reverse Stock Split Compliance Nasdaq Pieris Pharmaceuticals Stockholder Ownership
BRIEF published on 03/27/2024 at 13:05, 2 years ago Pieris Pharmaceuticals Announces New Strategy to Maximize Financial Potential Shareholder Value Pieris Pharmaceuticals Strategic Reorganization Milestone Payments Royalty Potential
PRESS RELEASE published on 03/27/2024 at 13:00, 2 years ago Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential Pieris Pharmaceuticals, Inc. announces strategic repositioning to maximize milestone and royalty potential from immuno-oncology assets. Cost-saving measures extend cash runway into 2027 Strategic Repositioning Cost-saving Measures Pieris Pharmaceuticals Milestone Payments Immuno-oncology Assets
Published on 04/09/2026 at 16:00, 1 hour ago Banff Half Marathon Completes 2025 Emissions Assessment, Supporting Climate Action with Karbon-X
Published on 04/09/2026 at 14:40, 2 hours 20 minutes ago Silver X Delivers Production Growth During the First Quarter of 2026
Published on 04/09/2026 at 14:00, 3 hours ago Orogen Royalties Announces Mineral Reserve and Resource Update on Producing Ermitaño Royalty
Published on 04/09/2026 at 13:30, 3 hours 30 minutes ago Datametrex Receives $6M Purchase Order for Data Centre from Fortune 500 Conglomerate
Published on 04/09/2026 at 13:30, 3 hours 30 minutes ago ESGold Advances Toward Production and Exploration Drilling as Mill Buildout Progresses in Parallel
Published on 04/09/2026 at 15:40, 1 hour 20 minutes ago Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc
Published on 04/09/2026 at 15:39, 1 hour 21 minutes ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 04/09/2026 at 15:39, 1 hour 21 minutes ago Form 8.3 - The Vanguard Group, Inc.: British Land Company plc, The
Published on 04/09/2026 at 15:57, 1 hour 3 minutes ago Filing of CNP Assurances SA 2025 universal registration document and 2025 Solvency and Financial Condition Reports
Published on 04/09/2026 at 07:00, 10 hours ago bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
Published on 04/08/2026 at 18:02, 22 hours 58 minutes ago Publication of the 2025 Universal Registration Document
Published on 04/08/2026 at 17:45, 23 hours 15 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 04/08/2026 at 12:58, 1 day 4 hours ago EURAZEO IS ASSIGNED A BBB CREDIT RATING (STABLE OUTLOOK) BY S&P AND A BBB CREDIT RATING (STABLE OUTLOOK) BY FITCH
